OpenAI is collaborating with Los Alamos National Laboratory (LANL) — known for creating the first nuclear weapon — to explore the use of artificial intelligence in bioscience research.
On July 9, OpenAI announced its partnership with LANL’s bioscience division to evaluate how AI models like GPT-4o can assist scientists in performing tasks in physical laboratories.
“This includes biological safety evaluations for GPT-4o and its currently unreleased real-time voice systems to understand how they could be used to support research in bioscience,” OpenAI stated.
Founded in 1943 to design and build the world’s first atomic bomb, LANL focused on military research for nearly 50 years. However, since the end of the Cold War in 1991, the lab has shifted towards civilian research and development.
Today, LANL’s bioscience division works on a variety of projects, including vaccine development, sustainability biotech, studying the impact of climate change on disease emergence, and detecting biothreats.
So relax, it’s for bioscience
GPT-4o is OpenAI’s latest “multimodal” large language model, allowing users to interact with the chatbot using voice, images, and text.
The partnership aims to tackle tasks such as cell transformation, cell culture, and cell separation. OpenAI plans to build on its previous bioscience work by incorporating “wet lab techniques,” training models to assist in complex tasks like mass spectrometry.
Additionally, OpenAI will explore new “modalities” of AI use in lab settings, with GPT-4o’s voice and visual inputs potentially expediting scientists’ learning processes.
OpenAI believes that this collaboration will contribute to ongoing research on biothreat risks.
Big Tech faces financial reckoning if human-level AI doesn’t happen soon
The new partnership comes as large tech companies — including Microsoft and Apple — begin to distance themselves from the AI startup due to growing regulatory concerns.
On July 10, Microsoft announced its withdrawal from OpenAI’s board, just a year after investing $13 billion in the firm. In June, European Union regulators revealed that OpenAI could face an EU antitrust investigation over its partnership with Microsoft.
Summary Review: The collaboration between OpenAI and Los Alamos National Laboratory marks a significant step forward in leveraging AI for bioscience research. By combining OpenAI’s advanced AI models like GPT-4o with LANL’s expertise in bioscience, the partnership aims to enhance scientific capabilities and address complex biological challenges. This initiative reflects OpenAI’s commitment to utilizing AI for beneficial applications while contributing to ongoing efforts in biothreat risk assessment. Despite facing regulatory scrutiny and distancing from major tech partners, OpenAI continues to advance its mission to explore innovative uses of AI in various scientific domains.
Disclaimer: Remember that nothing in this article and everything under the responsibility of Web30 News should be interpreted as financial advice. The information provided is for entertainment and educational purposes only. Investing in cryptocurrency involves inherent risks and potential investors should be aware that capital is at risk and returns are never guaranteed. It is imperative that you conduct thorough research and consult with a qualified financial advisor before making any investment decision.
